Transcode End Period Cash Flow from 2010 to 2024

RNAZ Stock  USD 0.34  0.04  10.53%   
Transcode Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Transcode Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.23 and arithmetic mean of  2,465,057. View All Fundamentals
 
End Period Cash Flow  
First Reported
2019-12-31
Previous Quarter
3.4 M
Current Value
1.9 M
Quarterly Volatility
M
 
Covid
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 48.1 K, Tax Provision of 0.0 or Net Interest Income of 15.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Transcode Therapeutics over the last few years. It is Transcode Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Transcode End Period Cash Flow Regression Statistics

Arithmetic Mean2,465,057
Geometric Mean573,517
Coefficient Of Variation218.44
Mean Deviation3,222,177
Median212,979
Standard Deviation5,384,581
Sample Variance29T
Range20.6M
R-Value0.48
Mean Square Error24.2T
R-Squared0.23
Significance0.07
Slope571,952
Total Sum of Squares405.9T

Transcode End Period Cash Flow History

20245.5 M
20232.8 M
2022M
202120.8 M
2020828 K
2019204.5 K

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow2.8 M5.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.